New horizons for treating castration resistant prostate cancer: Bipolar Androgen Therapy
The treatment of metastatic prostate cancer has evolved over the decades focusing on manipulation of the androgen receptor pathway with or without chemotherapy. Despite new drugs discovered with incrementing survival benefits, the disease continues to be fatal after development of castration resista...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Revinter Publicações Ltda.
2018-04-01
|
| Series: | Brazilian Journal of Oncology |
| Subjects: | |
| Online Access: | http://www.thieme-connect.de/DOI/DOI?10.5935/2526-8732.20180003 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850241548752519168 |
|---|---|
| author | Pedro Henrique Isaacsson Velho Katia Regina Marchetti Gabriel Passos Souza |
| author_facet | Pedro Henrique Isaacsson Velho Katia Regina Marchetti Gabriel Passos Souza |
| author_sort | Pedro Henrique Isaacsson Velho |
| collection | DOAJ |
| description | The treatment of metastatic prostate cancer has evolved over the decades focusing on manipulation of the androgen receptor pathway with or without chemotherapy. Despite new drugs discovered with incrementing survival benefits, the disease continues to be fatal after development of castration resistance and progression on abiraterone and enzalutamide. In this context, attempts of androgen pathway manipulation have led to the development of the Bipolar Androgen Therapy (BAT), which consists of a rapid transition from a castration state to supraphysiologic levels of testosterone and then back to castration levels. Pilot studies have shown this strategy to be safe and supported the development of further clinical trials. Phase II trials have demonstrated PSA response and disease control in a significant number of patients, including a possible resensitizing effect to enzalutamide. This promising strategy may in the future become another available option for these patients. |
| format | Article |
| id | doaj-art-9b4e9feeaa7b42bf99effc10cd6f3bd8 |
| institution | OA Journals |
| issn | 2526-8732 |
| language | English |
| publishDate | 2018-04-01 |
| publisher | Thieme Revinter Publicações Ltda. |
| record_format | Article |
| series | Brazilian Journal of Oncology |
| spelling | doaj-art-9b4e9feeaa7b42bf99effc10cd6f3bd82025-08-20T02:00:34ZengThieme Revinter Publicações Ltda.Brazilian Journal of Oncology2526-87322018-04-01144811010.5935/2526-8732.20180003New horizons for treating castration resistant prostate cancer: Bipolar Androgen TherapyPedro Henrique Isaacsson Velho0Katia Regina Marchetti1Gabriel Passos Souza2Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USAServiço de Oncologia Clínica – Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo, SP, BrasilServiço de Oncologia Clínica – Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo, SP, BrasilThe treatment of metastatic prostate cancer has evolved over the decades focusing on manipulation of the androgen receptor pathway with or without chemotherapy. Despite new drugs discovered with incrementing survival benefits, the disease continues to be fatal after development of castration resistance and progression on abiraterone and enzalutamide. In this context, attempts of androgen pathway manipulation have led to the development of the Bipolar Androgen Therapy (BAT), which consists of a rapid transition from a castration state to supraphysiologic levels of testosterone and then back to castration levels. Pilot studies have shown this strategy to be safe and supported the development of further clinical trials. Phase II trials have demonstrated PSA response and disease control in a significant number of patients, including a possible resensitizing effect to enzalutamide. This promising strategy may in the future become another available option for these patients.http://www.thieme-connect.de/DOI/DOI?10.5935/2526-8732.20180003Prostatic NeoplasmCastration-ResistantTestosteroneProstate-Specific AntigenNeoplasias da PróstataResistente à CastraçãoTestosteronaAntígeno Prostático Específico |
| spellingShingle | Pedro Henrique Isaacsson Velho Katia Regina Marchetti Gabriel Passos Souza New horizons for treating castration resistant prostate cancer: Bipolar Androgen Therapy Brazilian Journal of Oncology Prostatic Neoplasm Castration-Resistant Testosterone Prostate-Specific Antigen Neoplasias da Próstata Resistente à Castração Testosterona Antígeno Prostático Específico |
| title | New horizons for treating castration resistant prostate cancer: Bipolar Androgen Therapy |
| title_full | New horizons for treating castration resistant prostate cancer: Bipolar Androgen Therapy |
| title_fullStr | New horizons for treating castration resistant prostate cancer: Bipolar Androgen Therapy |
| title_full_unstemmed | New horizons for treating castration resistant prostate cancer: Bipolar Androgen Therapy |
| title_short | New horizons for treating castration resistant prostate cancer: Bipolar Androgen Therapy |
| title_sort | new horizons for treating castration resistant prostate cancer bipolar androgen therapy |
| topic | Prostatic Neoplasm Castration-Resistant Testosterone Prostate-Specific Antigen Neoplasias da Próstata Resistente à Castração Testosterona Antígeno Prostático Específico |
| url | http://www.thieme-connect.de/DOI/DOI?10.5935/2526-8732.20180003 |
| work_keys_str_mv | AT pedrohenriqueisaacssonvelho newhorizonsfortreatingcastrationresistantprostatecancerbipolarandrogentherapy AT katiareginamarchetti newhorizonsfortreatingcastrationresistantprostatecancerbipolarandrogentherapy AT gabrielpassossouza newhorizonsfortreatingcastrationresistantprostatecancerbipolarandrogentherapy |